Jpmorgan Chase & CO Ultragenyx Pharmaceutical Inc. Transaction History

Jpmorgan Chase & CO

  • $1.23 Trillion
  • Q4 2024

A detailed history of Jpmorgan Chase & CO transactions in Ultragenyx Pharmaceutical Inc. stock. As of the latest transaction made, Jpmorgan Chase & CO holds 205,787 shares of RARE stock, worth $8.76 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
205,787
Previous 213,210 3.48%
Holding current value
$8.76 Million
Previous $11.8 Million 26.9%
% of portfolio
0.0%
Previous 0.0%

Shares

19 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2024

Feb 12, 2025
SELL
$42.07 - $57.72 $312,285 - $428,455
-7,423 Reduced 3.48%
205,787 $8.66 Million
Q3 2024

Dec 26, 2024
SELL
$40.21 - $59.36 $314,241 - $463,898
-7,815 Reduced 3.54%
213,210 $11.8 Million
Q3 2024

Nov 08, 2024
SELL
$40.21 - $59.36 $314,241 - $463,898
-7,815 Reduced 3.54%
213,210 $11.8 Million
Q2 2024

Dec 26, 2024
BUY
$37.42 - $51.61 $292,437 - $403,332
7,815 Added 3.67%
221,025 $9.08 Million
Q2 2024

Aug 12, 2024
SELL
$37.42 - $51.61 $1.17 Million - $1.61 Million
-31,135 Reduced 12.35%
221,025 $9.08 Million
Q1 2024

Dec 26, 2024
BUY
$43.02 - $53.69 $1.68 Million - $2.09 Million
38,950 Added 18.27%
252,160 $11.8 Million
Q1 2024

May 10, 2024
SELL
$43.02 - $53.69 $1.11 Million - $1.38 Million
-25,782 Reduced 9.28%
252,160 $11.8 Million
Q4 2023

Dec 26, 2024
BUY
$31.73 - $49.19 $2.05 Million - $3.18 Million
64,732 Added 30.36%
277,942 $13.3 Million
Q4 2023

Feb 12, 2024
BUY
$31.73 - $49.19 $74,597 - $115,645
2,351 Added 0.85%
277,942 $13.3 Million
Q3 2023

Nov 14, 2023
SELL
$34.92 - $46.66 $1.31 Million - $1.75 Million
-37,554 Reduced 11.99%
275,591 $9.82 Million
Q2 2023

Aug 11, 2023
BUY
$37.35 - $52.15 $899,275 - $1.26 Million
24,077 Added 8.33%
313,145 $14.4 Million
Q1 2023

May 18, 2023
BUY
$36.99 - $48.71 $1.45 Million - $1.91 Million
39,200 Added 15.69%
289,068 $11.6 Million
Q1 2023

May 11, 2023
SELL
$36.99 - $48.71 $1.68 Million - $2.21 Million
-45,287 Reduced 15.34%
249,868 $10 Million
Q4 2022

Feb 13, 2023
SELL
$33.72 - $46.33 $594,011 - $816,149
-17,616 Reduced 5.63%
295,155 $13.7 Million
Q3 2022

Nov 14, 2022
BUY
$39.96 - $66.14 $711,847 - $1.18 Million
17,814 Added 6.04%
312,771 $13 Million
Q2 2022

Aug 11, 2022
SELL
$45.8 - $85.4 $283,318 - $528,284
-6,186 Reduced 2.05%
294,957 $17.6 Million
Q1 2022

May 11, 2022
SELL
$62.2 - $84.4 $1.27 Million - $1.72 Million
-20,411 Reduced 6.35%
301,143 $21.9 Million
Q4 2021

Feb 10, 2022
BUY
$73.71 - $87.86 $833,144 - $993,081
11,303 Added 3.64%
321,554 $27 Million
Q3 2021

Nov 12, 2021
BUY
$77.92 - $102.4 $24.2 Million - $31.8 Million
310,251 New
310,251 $28 Million

Others Institutions Holding RARE

# of Institutions
344
Shares Held
86.6M
Call Options Held
675K
Put Options Held
846K
View Full List

About Ultragenyx Pharmaceutical Inc.

RARE Quotes by TradingView
  • Ticker RARE
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 70,036,896
  • Market Cap $2.98B
  • Description
  • Ultragenyx Pharmaceutical Inc., a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Europe, and internationally. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast...
More about RARE
Track This Portfolio

Track Jpmorgan Chase & CO Portfolio

Follow Jpmorgan Chase & CO and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Jpmorgan Chase & CO, based on Form 13F filings with the SEC.

News

Stay updated on Jpmorgan Chase & CO with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email